Acute rheumatic fever (ARF) is a systemic inflammatory disease etiologically related to infection with group A streptococcus characterized by a broad spectrum of disorders of cellular and humoral immunity. To estimate the activity of the immunopathological process and to forecast myocardial derangement in ARF patients, measurements were made of neopterin in the serum of ARF patients. Nine men with ARF serving in the armed forces were examined. The control group comprised 24 donors. The reference group included 13 patients with dilated cardiomyopathy and 14 with chronic myocarditis. The mean level of neopterin in ARF patients was equal to 14.5 +/- 12.2 nM/l and was significantly higher than in the donors (5.0 +/- 2.0 nM/l). In patients with dilated cardiomyopathy and chronic myocarditis, it was 9 +/- 6 and 16 +/- 11 nM/l, respectively. On more careful clinical analysis the highest level of neopterin was recorded in 3 patients with impairment of the valvular apparatus of the heart. That level was observable during the whole period of the follow-up of the patients. In other patients, no impairment of the valves was detected, whereas the concentration of neopterin fell to normal. Therefore, the rise of the level of neopterin was described for the first time in patients with ARF. Besides, a relationship was found between the high level of neopterin and impairment of the valvular apparatus of the heart.
Download full-text PDF |
Source |
---|
EBioMedicine
January 2025
Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Section for Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway. Electronic address:
Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated participants who had received baricitinib. This sub-study aimed to investigate whether vaccination influences the safety profile of baricitinib in patients with severe COVID-19.
View Article and Find Full Text PDFArch Bone Jt Surg
January 2024
University of Health Sciences, Gulhane Faculty of Pharmacy, Department of Biochemistry, Ankara, Türkiye.
Objectives: In this study, the Kellgren and Lawrence system was used as the most common radiographic grading system for diagnosis of osteoarthritis in patients defined as Grade III and IV. It is aimed to reveal oxidative stress and cellular immunity status. In this context, the aim is to discuss possible risk parameters regarding disease process and treatment effectiveness.
View Article and Find Full Text PDFPol Merkur Lekarski
December 2024
UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE.
Objective: Aim: To study and analyze the treatment effectiveness in children with identified Coronavirus infection..
Patients And Methods: Materials and Methods: included the treatment and analysis of the study results of of children (n=68, aged 14.
Wiad Lek
December 2024
UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE.
Brain Behav Immun
February 2025
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm 17177, Sweden. Electronic address:
Long-term symptoms such as pain, fatigue, and cognitive impairments are commonly observed in individuals affected by coronavirus disease 2019 (COVID-19). Metabolites of the kynurenine pathway have been proposed to account for cognitive impairment in COVID-19 patients. Here, cerebrospinal fluid (CSF) and plasma levels of kynurenine pathway metabolites in 53 COVID-19 patients and 12 non-inflammatory neurological disease controls in Sweden were measured with an ultra-performance liquid chromatography-tandem mass spectrometry system (UPLC-MS/MS) and correlated with immunological markers and neurological markers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!